Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...
Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...
Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...
Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...
Zegfrovy (sunvozertinib) received accelerated FDA approval for NSCLC patients with EGFR exon 20 insertion mutations post-platinum-based chemotherapy progression. The Oncomine Dx Express Test was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback